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Abstract
Introduction The breast cancer susceptibility gene BRCA1 is
involved in the repair of double-strand breaks induced by
ionizing radiation and chemotherapy drugs. BRCA1 interacts
with coactivators such as p300 and CREB-binding protein
(CBP) to activate target gene transcription. Estrogen and
retinoic acid receptors (ER and RAR) also require coactivator
proteins for their ligand-dependent functions. Few studies have
suggested a role for nuclear hormone receptors in DNA repair.
Methods DNA damage and repair activity were quantified with
the use of single-cell gel electrophoresis and plasmid end-
joining assays. Cell cycle progression and apoptosis were
determined by bromodeoxyuridine and TdT-mediated dUTP nick
end labelling assays. Stable transfection was accomplished with
the lipofection procedure. Protein interaction and expression
were determined by immunoprecipitation and western blotting.
Results 17β-Estradiol (E2) and all-trans retinoic acid (RA) had
opposing effects on DNA damage and breast cancer cell
survival after double-strand break damage. Treatment with E2,
but not with RA, resulted in complex formation between ERα,
CBP, and BRCA1 in ER-positive cell lines. Mutant BRCA1
reduced the expression and activity of DNA damage repair
proteins but did not block nuclear hormone-dependent effects.
Mutant BRCA1 failed to form complexes with ERα and CBP,
which correlated with its ability to exert E2-independent effects
on DNA repair. Mutant BRCA1 inhibited cell cycle progression
and produced increased survival in cells with double-strand
breaks. Ectopic ERα expression reproduced the E2-mediated
effects on DNA damage, repair, and survival.
Conclusion The present study proposes a new mechanism by
which ER and RAR regulate BRCA1-mediated DNA repair by
means of CBP.
Introduction
Breast cancer is one of the leading causes of death in women.
Surgical removal of the tumor followed by radiation is the ther-
apeutic mainstay for early disease [1]. Inactivating mutations in
the tumor suppressor BRCA1 (breast cancer susceptibility
gene 1) are associated with significantly increased risk of
developing breast cancer [2]. The BRCA1 gene product con-
tains a RING zinc-finger motif at the amino terminus and two
BRCT (BRCA1 carboxyl-terminal) repeats [3]. The BRCT
repeat is found in a range of proteins involved in DNA repair
[4,5]. BRCA1 has been shown to regulate the DNA damage
response [6-9]. BRCA1 is involved in repair of double-strand
breaks induced by ionizing radiation and some chemotherapy
drugs [10]. Double-strand breaks induce chromosomal abnor-
malities such as aneuploidy, deletions, and translocations,
which are associated with cancer. Several chemotherapeutic
agents used in the treatment of breast cancer produce their
cytotoxic effects by creating DNA damage [11].
To repair double-strand breaks, mammalian cells use homolo-
gous recombination and end joining [12]. End joining is pre-
ferred in the G1 phase of the cell cycle when a second copy
of the DNA strand is unavailable. Cells that have experienced
double-strand breaks halt division and recruit repair factors
such as Rad51, Mre11, and Nbs1 to damaged sites in DNA
[13,14]. Mutations in double-strand break repair proteins give
rise to human diseases that manifest as cancer predisposition,
sensitivity to ionizing radiation, and chromosomal instability
BRCA1 = breast cancer susceptibility gene 1; BRCT = BRCA1 carboxyl-terminal; BrdU = bromodeoxyuridine; CBP = CREB-binding protein; Cdk 
= cyclin-dependent kinase; E2 = 17β-estradiol; ER = estrogen receptor; RA = all-trans retinoic acid; RAR = retinoic acid receptor; siRNA = short 
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[15]. Mice containing null mutations in several of these factors
exhibit chromosomal abnormalities and embryonic lethality
[16].
Among the most important nuclear hormone receptors
expressed by breast cancer cells are those for estrogen and
retinoic acid [17]. Estrogens such as 17β-estradiol (E2) have
been shown to markedly enhance the proliferation of mammary
gland epithelium [18]. In contrast, several natural and synthetic
retinoids have been shown to inhibit the proliferation of these
cells and have been used as chemotherapy drugs in the treat-
ment of breast cancer [19]. Estrogen receptors (ER) and retin-
oic acid receptors (RAR) are members of a family of ligand-
dependent transcription factors that include steroid, thyroid,
and vitamin D receptors [20]. Both ER and RAR have func-
tional domains for DNA binding, ligand binding, dimerization,
and transcriptional activation. Nuclear receptors and BRCA1
require coactivator proteins such as p300 and its close rela-
tive CREB-binding protein (CBP) to activate target gene tran-
scription [21]. CBP/p300 interacts with ER and RAR in their
ligand-bound conformation to induce gene expression [22].
CBP/p300 has histone acetyltransferase activity, permitting
histone disassembly and transcriptional activation [23]. CBP/
p300 has also been shown to interact with and enhance the
function of BRCA1 [24].
Although the effects of E2 and all-trans retinoic acid (RA) on
the proliferation of human breast cancer cells have been
known for many years, only recently have gene expression pro-
filing studies suggested a role for these hormones in DNA
repair [25,26]. The present study proposes a new mechanism
by which ER and RAR regulate BRCA1-mediated DNA repair
via CBP.
Materials and methods
Cell culture
The human breast cancer cell lines used in this study (MCF7,
T47D, MDA-MB-231, and MDA-MB-468) were purchased
from the American Type Culture Collection and cultured in
Dulbecco's modified Eagle's medium without phenol red (Inv-
itrogen), 10% charcoal-resin-treated fetal bovine serum
(Hyclone), and 40 µg/ml gentamicin (Invitrogen) in a humidi-
fied atmosphere of 5% CO2 at 37°C. Cultures were treated
with 100 nM estradiol (Sigma), RA (Sigma), or vehicle for 8
hours before the addition of 30 µg/ml etoposide (Sigma) for
16 hours or a single 3 Gy dose of ionizing radiation (60Co
source; USC/Norris Comprehensive Cancer Center) to
induce DNA double-strand breaks. Treatment with 10 µg/ml
cisplatin (which induces bulky adduct formation; Sigma) was
used to control for type of DNA damage. To determine
whether survival signals in this model system were mediated
by protein kinases or second messengers, cultures were
treated individually with 10 µM PD98059 (MEK inhibitor;
Alexis Biochemicals), 5 µM SB203580 (p38 inhibitor; Alexis
Biochemicals), 5 µM SP600125 (Jnk inhibitor; Calbiochem),
10  µM SH5 (Akt inhibitor, Alexis Biochemicals), 1 µM
Go6976 (PKC inhibitor; Alexis Biochemicals), 10 µM
LY294002 (phosphoinositide 3-kinase inhibitor; Alexis Bio-
chemicals), or 1 µM U73122 (phospholipase Cγ inhibitor;
Alexis Biochemicals) for 8 hours before addition of other
compounds.
Programmed cell death analysis
Cells were fixed in 4% paraformaldehyde (pH 7.4), and perme-
abilized with 0.1% Triton X-100 (Sigma) and 0.1% sodium cit-
rate for 2 minutes on ice. A mouse IgM anti-human Fas
antibody (Molecular Biology Laboratories, Woburn, MA, USA)
that induces apoptosis in sensitive cell lines was used as the
positive control (data not shown). An isotype-matched control
antibody was used as the negative control. After being
washed with PBS, cells were incubated with fluorescein-
dUTP and terminal deoxynucleotidyl transferase for 60 min-
utes at 37°C in accordance with the manufacturer's recom-
mendations (Roche Molecular Biochemicals). After being
washed three times in PBS, apoptotic cells were revealed by
fluorescence microscopy.
DNA damage analysis
DNA damage was quantified by single-cell gel electrophoresis
[27,28]. Drug-treated cells were mixed with 0.5% low-melting-
point agarose and added to microscope slides coated with
1.5% agarose. Cells were denatured with alkali (pH 13), sub-
jected to electrophoresis at 0.86 V/cm for 25 minutes, and
stained with ethidium bromide. The tail moment (DNA migra-
tion × tail intensity) of 50 randomly selected cells was ana-
lyzed from each slide by using Komet imaging software
(Kinetic Imaging).
End joining assay
The well-characterized plasmid end-joining assay was used to
evaluate nonhomologous end joining in breast cancer cell lines
[29-31]. Reactions were performed in end-joining buffer con-
taining 250 ng of dephosphorylated pBluescript II SK- cut with
EcoRI and XhoI restriction enzymes and 20 µg of T47D (ER+)
or MDA-MB-468 (ER-) cellular extract in a final 20 µl volume at
25°C for 1 hour. The reactions were terminated and 20% of
each sample was transformed into E. coli strain DH5α to
quantify end-joining activity.
Western blotting
Total cellular protein (75 µg) from breast cancer cell lines was
separated by SDS-PAGE on 10% resolving gels under dena-
turing and reducing conditions. Separated proteins were elec-
troblotted to poly(vinylidene difluoride) membranes in
accordance with the manufacturer's recommendations
(Roche Molecular Biochemicals). Blots were incubated with
antibodies against human double-strand break repair or cell
cycle regulatory proteins for 16 hours at 4°C. After being
washed in Tris-buffered saline (pH 7.4) containing 0.1%
Tween 20 (TBST), blots were incubated for 30 minutes atAvailable online http://breast-cancer-research.com/content/8/1/R1
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20°C with anti-IgG secondary antibody conjugated to horse-
radish peroxidase. After extensive washing in TBST, bands
were revealed by the enhanced chemiluminescence method
(Roche Molecular Biochemicals).
Immunoprecipitation
Cultures were lysed in 50 mM HEPES (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM dithiothreitol, 1%
Nonidet P40, 10% glycerol, 1 mM NaF, 0.1 mM sodium
orthovanadate, and protease inhibitors for 30 minutes at 4°C.
Lysates were centrifuged at 10,000 g for 10 minutes, and anti-
CBP antibody (Santa Cruz Biotechnology) was incubated with
the supernatants for 1 hour at 4°C. Preimmune IgG was used
as a negative control antibody for immunoprecipitation. Anti-
gen-antibody complexes were precipitated with anti-CBP anti-
body and protein A/G agarose beads for 1 hour at 4°C.
Immunoprecipitated proteins were washed three times with 1
ml of lysis buffer. Samples were boiled in Laemmli buffer for 3
minutes, separated by SDS-PAGE, and blotted to poly(vinyli-
dene difluoride) membranes. Blots were incubated with anti-
ERα, anti-RARα, and anti-BRCA1 antibodies followed by anti-
CBP antibody to ensure equal amounts of immunoprecipitated
protein in each lane.
Transfections
T47D and MDA-MB-468 cells were stably transfected with a
BRCA1 mutant construct lacking the carboxyl-terminal 276
amino acid residues containing the BRCT repeat region
(BRCA1 construct kindly provided by Dr Kenneth Cowan) or
G418 resistance plasmid with the use of Lipofectamine rea-
gent in accordance with the manufacturer's recommendations
(Invitrogen). MDA-MB-468 cells were separately transfected
with an ERα expression vector (kindly provided by Dr Ronald
Evans) or G418 resistance plasmid. Cells were selected in
400 µg/ml G418 for 14 days. Resistant clones were picked
for expansion and characterization. Separate cultures were
transiently transfected with 50 nM BRCA1 short interfering
RNA (siRNA; Santa Cruz Biotechnology) or unrelated siRNA
with the use of Lipofectamine, before being harvested for fur-
ther analysis.
Bromodeoxyuridine incorporation analysis
Cells were incubated with 10 µM bromodeoxyuridine (BrdU)
for 1 hour. After being washed in PBS, cells were fixed in 70%
ethanol, 50 mM glycine (pH 2) for 30 minutes at -20°C. After
extensive washing in PBS, cells were incubated with mouse
anti-BrdU primary antibody at 37°C for 30 minutes (Roche
Molecular Biochemicals). After being washed in PBS, cells
were incubated with anti-mouse IgG secondary antibody con-
jugated to fluorescein at 37°C for 30 minutes. After extensive
washing in PBS, BrdU-positive cells were revealed by fluores-
cence microscopy. The number of positive cells was
expressed as a percentage of total cells counted in 10 high-
power fields.
Statistical analysis
Parametric data were analyzed by t test and analysis of vari-
ance; p  < 0.05 was considered statistically significant. All
experiments were performed at least three times.
Results
We treated four human breast cancer cell lines with 100 nM
E2 or RA, followed by etoposide to induce double-strand DNA
breaks. As shown in Fig. 1a, treatment with etoposide resulted
in 60 to 70% TdT-mediated dUTP nick end labelling (TUNEL)-
positive cells within 16 hours. Pretreatment with E2 resulted in
increased survival of ER-positive MCF7 and T47D breast can-
cer cell lines (40% TUNEL-positive cells; p < 0.005) com-
pared with vehicle-treated control cultures. No effect of E2
was observed in ER-negative MDA-MB-231 and MDA-MB-
468 cell lines. In contrast, treatment with RA increased the
number of apoptotic cells to 80% in all cell lines (p < 0.001).
In cultures simultaneously treated with E2 and RA, the pro-sur-
vival effect of E2 was still observed in ER-positive cells but not
in ER-negative lines. Similar effects of these ligands were
observed when ionizing radiation was used to induce double-
strand breaks (Fig. 1b). However, no effects of E2 or RA were
observed in cisplatin-treated cultures, indicating that the
effects of these ligands were specific for survival after double-
strand breaks but not adduct formation (data not shown). We
concluded that E2 and RA had opposing effects on breast
cancer cell survival after double-strand DNA break damage.
To determine whether the pro-survival effects of E2 were
mediated by kinase signaling or by second messengers, we
treated ER-positive MCF7 and T47D cells with selective inhib-
itors of these pathways before treatment with E2 and etopo-
side. As shown in Fig. 1c, treatment with MEK, JNK, p38, Akt,
PKC, phosphoinositide 3-kinase, or phospholipase Cγ inhibi-
tors had no effect on the pro-survival effect of E2 as deter-
mined by TUNEL assay. These results indicate that signaling
p a t h w a y s  u p s t r e a m  o f  E R  d o  not regulate the pro-survival
effect of E2 in cells exposed to DNA double-strand break
damage.
To determine whether the effects of E2 and RA on cell survival
were correlated with the extent of double-strand break dam-
age, we performed single-cell gel electrophoresis on human
breast cancer cell lines treated with these ligands before
etoposide. As shown in Fig. 1d, E2 decreased the extent of
DNA damage by 40% in ER-positive cell lines (p < 0.03). No
effect of E2 on DNA damage was observed in ER-negative cell
lines. In contrast, RA increased relative DNA damage levels by
10 to 20% in all cell lines examined (p < 0.01). In cells treated
simultaneously with E2 and RA, relative DNA damage levels
decreased by an amount similar to that after treatment with E2
alone. These results indicate that the cell survival effects of E2
and RA on human breast cancer cell lines are correlated with
relative DNA damage levels in cultures treated with these lig-
ands followed by etoposide.Breast Cancer Research    Vol 8 No 1    Crowe and Lee 
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Figure 1
E2 inhibits and RA enhances DNA damage-mediated apoptosis in human breast cancer cell lines E2 inhibits and RA enhances DNA damage-mediated apoptosis in human breast cancer cell lines. (a) Estrogen receptor (ER)-positive human breast 
cancer cell lines (MCF7 and T47D) and ER-negative lines (MDA-MB-231 and MDA-MB-468) were treated with 17β-estradiol (E2) or all-trans retin-
oic acid (RA) alone or in combination (E2/RA) prior to etoposide induced DNA damage. Vehicle-treated cells were used as the negative control 
(con). Apoptotic cells were identified by TdT-mediated dUTP nick end labeling (TUNEL) assay. Error bars indicate SEM. (b) The human breast can-
cer cell lines identified above were treated with E2 or RA alone or in combination (E2/RA)before treatment with 3 Gy of ionizing radiation to induce 
double-strand DNA breaks. Vehicle-treated cells were used as the negative control (con). Apoptotic cells were identified by TUNEL assay. Error bars 
indicate SEM. (c) The pro-survival effects of E2 were not mediated by MAPK, PKC, phosphoinositide 3-kinase, phospholipase Cγ, or Akt/PKB sign-
aling in human breast cancer cell lines. ER-positive breast cancer cell lines MCF7 and T47D were pretreated with PD98059 (PD), SP600125, (SP), 
SB203580 (SB), SH5, (Akt/PKB inhibitor), Go6976 (Go), LY294002 (LY), or U73122 (U) as indicated in Materials and Methods. Vehicle-treated 
cells were used as the negative control (con) for the TUNEL assay. (d) E2 inhibits and RA increases the extent of DNA damage in etoposide-treated 
human breast cancer cell lines. The indicated ER-positive and ER-negative cell lines were treated with E2 or RA alone or in combination (E2/RA), as 
described above, before exposure to etoposide. Vehicle-treated cells were used as the negative control (con). Relative DNA damage was quantified 
as described in Materials and Methods. (e) E2 enhances and RA inhibits DNA double-strand break repair in human breast cancer cell lines. The indi-
cated cell lines were treated with E2 or RA alone or in combination (E2/RA) as described above. Vehicle-treated cells were used as the negative 
control (con). The plasmid end-joining assay was used to quantify DNA repair activity. (f) E2 or RA treatment does not affect double-strand break 
repair protein expression in human breast cancer cell lines. The indicated lines were treated with E2 or RA as described above. Vehicle-treated cells 
were used as the negative control (con). Protein extracts from treated cells were subjected to western blotting with the anti-human antibodies indi-
cated at the left. (g) Complex formation of BRCA1 with CBP and ERα in E2-treated but not RA-treated T47D cells (upper panel). Vehicle-treated 
cells were used as the negative control. The CBP coactivator protein was immunoprecipitated from treated cultures with anti-CBP antibody (IP 
CBP). Preimmune IgG was used as the negative control for immunoprecipitation. Immunoprecipitates were subjected to western blotting to detect 
interaction with ERα, retinoic acid receptor α (RARα), and BRCA1 by using the antibodies indicated at the left. Blots were stripped and incubated 
with anti-CBP antibody to detect relative amounts of immunoprecipitated protein in each lane. These experiments were performed three times with 
similar results; representative blots are shown.Available online http://breast-cancer-research.com/content/8/1/R1
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To determine whether effects of E2 and RA on DNA damage
could result from changes in DNA repair activity, we analyzed
plasmid end joining in ligand-treated human breast cancer cell
lines. As shown in Fig. 1e, E2 increased the number of trans-
formants in the end joining assay by 20% when extract from
ER-positive cell lines was used (p < 0.006). No effect of E2
was observed with ER-negative cell extract. Treatment with
RA inhibited plasmid end joining in all cell extracts by 30% (p
< 0.002). In extracts from cells treated simultaneously with E2
and RA, the number of transformants increased by an amount
similar to that after treatment with E2 alone with extract from
ER-positive cells. These results indicate that the effects of E2
and RA on DNA damage were correlated with DNA repair
activity in human breast cancer cell lines.
To determine whether the effects of E2 and RA on DNA repair
activity were the result of changes in repair protein expression,
we examined the expression of double-strand break repair
gene products by western blotting. As shown in Fig. 1f, E2 and
RA did not affect the expression of seven double-strand break
repair proteins in ER-positive and ER-negative human breast
cancer cell lines. These results indicated that the effects of E2
and RA on DNA repair activity were not the result of changes
in repair protein expression. We therefore wondered whether
ER and RAR coactivator proteins such as CBP might differen-
tially associate with these receptors and regulators of DNA
repair such as BRCA1 in human breast cancer cell lines. As
shown in Fig. 1g, treatment with E2 induced complex forma-
tion between ERα, BRCA1, and CBP in ER-positive T47D
cells (upper panel). This complex was not observed in ER-neg-
ative MDA-MB-468 cells treated with E2 (lower panel). Treat-
ment with RA showed recruitment of CBP to RARα in both cell
lines, but BRCA1 was not detected in these complexes. Low-
level association of BRCA1 with CBP was observed in vehi-
cle-treated cells, but neither ERα nor RARα was detected in
these complexes. No protein interactions were observed when
preimmune IgG was used in place of anti-CBP antibody in the
immunoprecipitations. These results indicate that treatment
with E2 results in complex formation between ERα, CBP, and
BRCA1 in ER-positive breast cancer cell lines; treatment with
RA recruits CBP but not BRCA1 to RARα in both ER-positive
and ER-negative cell lines.
Given that recruitment of BRCA1 to the ERα/CBP complex
was correlated with increased DNA repair and survival, which
was not observed in RA-treated cells, we wished to determine
the contribution of BRCA1 to these processes. To accomplish
this task, we stably transfected T47D and MDA-MB-468
breast cancer cells with a carboxyl-terminal truncation mutant
of BRCA1. This BRCA1 mutant lacked the BRCT repeat
region believed to be involved in DNA repair [4,5]. Expression
of the endogenous BRCA1 gene product and the mutant con-
struct is shown by the western blot in Fig. 2a. To determine the
effects of the BRCA1 mutant on the expression of double-
strand break repair proteins, we treated stable T47D and
MDA-MB-468 mutant and control clones with etoposide for
16 hours. As shown in Fig. 2b, treatment with etoposide
induced the expression of Rad52, Rad54, XRCC2, XRCC3,
and XRCC4 in T47D control clones. The mutant BRCA1 pro-
tein blocked the induction of all five of these genes by etopo-
side. In contrast, expression of the mismatch repair protein
MSH2 and the nucleotide excision repair gene product XPA
was unaffected by treatment with the mutant BRCA1 or etopo-
side. Similar effects of the BRCA1 mutant were observed with
ER-positive MCF7 and ER-negative MDA-MB-231 cells (data
not shown). These results indicate that mutant BRCA1 inhibits
the expression of DNA damage repair proteins in human
breast cancer cell lines.
To determine whether the mutant BRCA1 protein could block
the protective effects of E2 on ER-positive breast cancer cell
lines, we treated T47D stable clones with E2 or RA followed
by etoposide. The ER-negative MDA-MB-468 clones served
as controls in these experiments. As shown in Fig. 2c, E2 (p <
0.002) and RA (p < 0.008) reproduced the effects on relative
DNA damage levels in T47D control clones first seen in
untransfected cells. In contrast, relative DNA damage levels
were twofold higher in T47D clones expressing the mutant
BRCA1 protein (p < 0.0002). However, the mutant BRCA1
was unable to block either the protective effects of E2 or the
deleterious effects of RA on relative DNA damage levels in
these cells. The E2 effect again dominated in cultures treated
simultaneously with E2 and RA. DNA damage was also
greater in ER-negative MDA-MB-468 clones expressing
mutant BRCA1 but was unresponsive to E2. Treatment with
RA increased relative DNA damage levels by 20% in these
clones. These results indicate that mutant BRCA1 expression
was correlated with increased etoposide-mediated DNA dam-
age in human breast cancer cell lines but did not block nuclear
hormone-dependent effects.
To determine whether increased DNA damage as the result of
mutant BRCA1 resulted from decreased repair activity, we
used lysates from E2 and RA breast cancer clones in the end-
joining assay. As shown in Fig. 2d, expression of the BRCA1
mutant decreased end joining by 60% with lysate from T47D
clones (p < 0.04). The mutant BRCA1 gene product did not
block the effects of E2 and RA on end joining in this assay.
Expression of the mutant BRCA1 also decreased end joining
i n M D A -M B - 4 6 8  c lo n es  b y  5 0 %  ( p  < 0.04). Treatment of
these clones with RA produced a 25% reduction in end joining
in these assays (p < 0.02), but treatment with E2 had no effect
in the ER-negative clones. These results indicated that expres-
sion of the BRCA1 mutant resulted in decreased DNA repair
activity in ER-positive and ER-negative breast cancer clones.
We expected the decreased DNA repair activity observed in
BRCA1 mutant clones to correlate with decreased survival in
breast cancer cells exposed to etoposide. However, as shown
in Fig. 2e, expression of the BRCA1 mutant resulted inBreast Cancer Research    Vol 8 No 1    Crowe and Lee 
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Figure 2
BRCA1 inhibition decreases DNA damage repair and cell survival in human breast cancer cell lines BRCA1 inhibition decreases DNA damage repair and cell survival in human breast cancer cell lines. (a) Expression of dominant-negative BRCA1 in 
human breast cancer cell lines. T47D and MDA-MB-468 cells were stably transfected with the BRCA1 carboxyl-terminal truncation mutant 
(BRCA1delC) or neomycin expression vector (neo). Protein extracts from these clones were subjected to western blotting with anti-BRCA1 anti-
body. Anti-β-actin antibody was used to determine relative amounts of protein in each lane. Representative blots are shown. (b) BRCA1 inhibition 
decreases the expression of double-strand break repair proteins in human breast cancer cell lines. T47D or MDA-MB-468 BRCA1delC or neomy-
cin-resistant control (neo) clones were treated with etoposide (etopo) or vehicle prior to western blotting with antibodies indicated at the left. Blots 
were stripped and incubated with anti-β-actin antibody to determine relative amounts of protein in each lane. Representative blots are shown. (c) 
T47D and MDA-MB-468 BRCA1delC clones exhibit increased DNA damage when treated with etoposide. BRCA1delC or neomycin-resistant con-
trol clones (neo) were pretreated with E2RA alone or in combination (E2/RA) before exposure to etoposide. Vehicle-treated cultures were used as 
the negative control (con). Relative DNA damage was quantified as described in Materials and Methods. Error bars indicate SEM. (d) T47D and 
MDA-MB-468 BRCA1delC clones exhibit decreased DNA repair activity. BRCA1delC or neomycin-resistant control clones (neo) were pretreated 
with E2 or RA alone or in combination (E2/RA). Vehicle-treated cultures were used as the negative control (con). The plasmid end-joining assay was 
used to quantify DNA repair activity. Error bars indicate SEM. (e) Increased cell survival in etoposide-treated T47D and MDA-MB-468 BRCA1delC 
clones. Neomycin control clones were used as controls. Cultures were pretreated with E2 or RA alone or in combination (E2/RA). Vehicle-treated 
cultures were used as the negative control (con). Cell death was quantified by TdT-mediated dUTP nick end labelling assay. These experiments were 
repeated three times with similar results. Error bars indicate SEM. (f) No complex formation of BRCA1delC with CBP and estrogen receptor α 
(ERα) in T47D and MDA-MB-468 cells. Stable clones expressing BRCA1delC were treated with E2 or RA as described in Materials and Methods. 
Vehicle-treated cells were used as the negative control. The CBP coactivator protein was immunoprecipitated from treated cultures with anti-CBP 
antibody (IP CBP). Preimmune IgG was used as the negative control for immunoprecipitation. Immunoprecipitates were subjected to western blot-
ting to detect interaction with ERα, retinoic acid receptor α (RARα), and BRCA1 by using the antibodies indicated at the left. Blots were stripped 
and incubated with anti-CBP antibody to detect relative amounts of immunoprecipitated protein in each lane. In contrast, both wild-type and mutant 
BRCA1 immunoprecipitated from both cell lines with anti-BRCA1 antibody (lower panel). These experiments were performed three times with similar 
results; representative blots are shown.Available online http://breast-cancer-research.com/content/8/1/R1
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increased survival of both T47D and MDA-MB-468 clones.
Etoposide treatment produced only 35% TUNEL-positive cells
in T47D clones expressing the BRCA1 mutant construct,
compared with 50% in control cultures (p < 0.0005). Similarly,
etoposide treatment resulted in 45% TUNEL-positive MDA-
MB-468 mutant cells, compared with 60% of control clones (p
< 0.03). The pro-survival effects of E2 and pro-apoptotic
effects of RA were not blocked by the BRCA1 mutant in T47D
clones. RA also had pro-apoptotic effects on MDA-MB-468
clones expressing the BRCA1 mutant, but E2 had no effect on
the ER-negative line. These results indicate that despite
decreased DNA repair as the result of mutant BRCA1, this
construct also produced increased survival in breast cancer
cells with DNA double-strand breaks.
We hypothesized that the failure of the mutant BRCA1 protein
to affect E2-mediated DNA repair might have been due to
decreased ability of the truncated tumor suppressor to interact
with CBP. To test this hypothesis we immunoprecipitated
CBP from E2-treated and RA-treated stable T47D and MDA-
MB-468 clones expressing the truncated BRCA1 protein. As
shown in Fig. 2f, the larger wild-type BRCA1 protein immuno-
precipitated with CBP in both T47D and MDA-MB-468
clones. However, the mutant BRCA1 protein was not
detected in these immunoprecipitates even though it was
detected in these cells when anti-BRCA1 antibody was used
in the immunoprecipitation. ERα formed complexes with wild-
type BRCA1 and CBP in E2-treated T47D clones but not in
MDA-MB-468 clones, a similar pattern to that observed in the
parental breast cancer cell lines. RARα became associated
with CBP but not with wild-type BRCA1 in RA-treated T47D
and MDA-MB-468 clones. These results indicate that the trun-
cated BRCA1 fails to form complexes with ERα and CBP,
which correlates with its ability to exert E2 -independent
effects on DNA damage repair.
To confirm that loss of function was responsible for the effects
of the BRCA1 mutant, we transfected cultures of breast can-
cer cell lines with BRCA1 siRNA. As shown in Fig. 3a, siRNA
transfection reduced BRCA1 protein expression by more than
90% in T47D and MDA-MB-468 cells. Decreased BRCA1
expression doubled the relative DNA damage in both cell lines
(p < 0.0001) but did not block hormone-dependent effects
(Fig. 3b). BRCA1 siRNA transfection inhibited DNA damage
repair in both cell lines by 40 to 50% (p < 0.05) but did not
block hormone-dependent effects (Fig. 3c). However,
decreased BRCA1 expression resulted in increased cell death
after exposure to etoposide (Fig. 3d; p < 0.05 for T47D, p <
0.01 for MDA-MB-468). These results indicate that BRCA1
loss of function produces increased DNA damage and cell
death as a result of reduced repair capability.
Given that DNA damage agents target dividing cells, we
hypothesized that cell cycle inhibition due to the mutant
BRCA1 could result in greater resistance to etoposide. BrdU
incorporation analysis demonstrated that the mutant BRCA1
transgene (but not siRNA treatment) inhibited S-phase pro-
gression in both T47D (17% versus 10% positive cells; p <
0.03) and MDA-MB-468 (20% versus 16%; p < 0.02) lines
(Fig. 4a). The effect of the BRCA1 mutant was greater than
that of treatment of control clones with etoposide. Treatment
of BRCA1 clones with etoposide further reduced BrdU incor-
poration (17% versus 7% positive cells in T47D and 20% ver-
sus 13% in MDA-MB-468 lines). We also examined the
expression of cell cycle regulatory proteins in both lines (Fig.
4b). Expression of the mutant BRCA1 reduced epidermal
growth factor receptor levels below the limit of detection for
western blotting in MDA-MB-468 clones. Similarly, expression
of the growth factor receptor c-Met was completely inhibited
in T47D clones expressing mutant BRCA1. Expression of the
G2-phase protein cyclin B was reduced to undetectable levels
in etoposide-treated T47D clones expressing the mutant
BRCA1 construct. Expression of the G1-phase protein cyclin
E was inhibited twofold in T47D clones expressing the mutant
BRCA1. Treatment with etoposide induced cyclin-dependent
kinase (Cdk)2 levels in these clones, which was inhibited five-
fold by the mutant BRCA1. This construct also reduced
expression of the G1 kinases Cdk4 and Cdk6 to nearly unde-
tectable levels in MDA-MB-468 clones. These results indicate
that the mutant BRCA1 construct inhibited cell cycle progres-
sion, which correlated with increased resistance to etoposide.
To determine whether ERα was sufficient to confer E2 medi-
ated DNA damage repair and increased survival on ER-nega-
tive breast cancer cell lines, we stably transfected MDA-MB-
468 cells with an ERα expression vector. Expression of ERα
protein in these clones in comparison with MDA-MB-468 vec-
tor control cells and G418-resistant ER-positive T47D cells is
shown in Fig. 5a. Ectopic ERα formed complexes with BRCA1
and CBP in E2-treated MDA-MB-468 clones to a similar
degree to that observed in T47D cells (Fig. 5b). RARα failed
to form complexes with BRCA1 in RA-treated cells. These
clones were treated with E2 and RA alone or in combination
before exposure to etoposide. As shown in Fig. 5c, ectopic
ERα expression in MDA-MB-468 cells resulted in E2-medi-
ated decreases in relative DNA damage levels of 25% (p <
0.002). This effect was also observed when E2 and RA were
used in combination. ERα expression in MDA-MB-468 clones
had no effect on RA-mediated DNA damage. G418-resistant
MDA-MB-468 control clones did not exhibit E2-mediated
decreases in relative DNA damage levels. The effects of E2
and RA in G418-resistant ER-positive T47D clones were sim-
ilar to those observed in the parental cell line. Decreased DNA
damage was correlated with increased DNA repair activity in
E2-treated ERα-expressing MDA-MB-468 clones, as demon-
strated by the end-joining assay (Fig. 5d). Results obtained
with T47D and MDA-MB-468 G418-resistant control clones
were similar to those observed in the parental cell lines.
Increased resistance to etoposide and survival was also
observed in the E2-treated MDA-MB-468 clones (Fig. 5e).Breast Cancer Research    Vol 8 No 1    Crowe and Lee 
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Treatment with RA decreased cell survival to a degree similar
to that observed in the MDA-MB-468 parental line. Results
obtained with T47D and MDA-MB-468 control clones were
similar to those observed for the parental cell lines. These
results indicate that ectopic ERα expression was sufficient to
produce the E2-mediated effects on relative DNA damage lev-
els, DNA repair, and survival in etoposide-treated MDA-MB-
468 clones.
Discussion
One of the key findings of this study is the protective effects of
E2 on ER-positive breast cancer cell lines after DNA damage.
This effect was ER dependent because stable transfection of
this expression vector into ER-negative breast cancer cell lines
resulted in decreased DNA damage and increased survival
when these cells were treated with E2 before etoposide.
These results contrast with previous studies in which metabo-
lites of E2 were shown to cause DNA damage by the formation
of direct adducts or the generation of reactive oxygen species
(reviewed in [32]). Increased oxidative DNA damage has been
detected in target tissues after exposure to estrogen, and a
low-activity form of catechol-O-methyltransferase has been
associated with an increased risk of breast cancer. Glutath-
ione-depleted MCF7 cells treated with E2 exhibited significant
increases in formation of 8-oxo-2'-deoxyguanosine [33]. Treat-
ment of MCF7 cells with E2 resulted in a decreased ability to
metabolize peroxide and increased sensitivity to peroxide-
induced DNA damage [34]. These effects were not observed
in ER-negative breast cancer cell lines. Anti-estrogens have
been shown to activate the detoxifying enzyme quinone
reductase and protect against E2-mediated DNA damage
[35]. Our present study does not rule out these DNA damage
effects but suggests a new role for E2 in DNA damage repair
and cell survival that is regulated by complex formation with
coactivator proteins and BRCA1.
Double-strand DNA breaks have been shown to induce a
number of growth factor signaling pathways [36]. However,
we determined that the protect i v e  e f f e c t s  o f  E 2  w e r e  n o t
dependent on a number of upstream kinases and second
Figure 3
BRCA1 depletion decreases DNA damage repair and cell survival in human breast cancer cell lines BRCA1 depletion decreases DNA damage repair and cell survival in human breast cancer cell lines. (a) Reduced BRCA1 expression in human 
breast cancer cell lines transfected with siRNA. T47D and MDA-MB-468 cells were transiently transfected with BRCA1 siRNA or an unrelated 
siRNA (mock). Protein extracts from these clones were subjected to western blotting with anti-BRCA1 antibody. Anti-β-actin antibody was used to 
determine relative amounts of protein in each lane. Representative blots are shown. (b) Decreased BRCA1 expression results in increased DNA 
damage when treated with etoposide. T47D and MDA-MB-468 lines transfected with BRCA1 or unrelated siRNA (mock) were pretreated with 17β-
estradiol (E2) or all-trans retinoic acid (RA) alone or in combination (E2/RA) before exposure to etoposide. Vehicle-treated cultures were used as the 
negative control (con). Relative DNA damage was quantified as described in Materials and Methods. Error bars indicate SEM. (c) Decreased 
BRCA1 expression results in decreased DNA repair activity. T47D or MDA-MB-468 lines transfected with BRCA1 or unrelated siRNA (mock) were 
pretreated with E2 or RA alone or in combination (E2/RA). Vehicle-treated cultures were used as the negative control (con). The plasmid end-joining 
assay was used to quantify DNA repair activity. Error bars indicate SEM. (d) Decreased BRCA1 expression results in decreased cell survival in 
etoposide-treated T47D and MDA-MB-468 lines transfected with BRCA1 siRNA. Cultures transfected with unrelated siRNA (mock) were used as 
controls. Cultures were pretreated with E2 or RA alone or in combination (E2/RA). Vehicle-treated cultures were used as the negative control (con). 
Cell death was quantified by TdT-mediated dUTP nick end labelling assay. These experiments were repeated three times with similar results. Error 
bars indicate SEM.Available online http://breast-cancer-research.com/content/8/1/R1
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messengers. It has been known for many years that ER is
phosphorylated by MAPK [37]. Since then, ER has been
shown to be a substrate for other kinases such as Cdk2 and
Akt, which increase transcriptional activation of the receptor
[38,39]. However, our data suggest that the actions of these
kinases on ER transcriptional activation may not be required to
protect breast cancer cell lines against DNA damage, and E2
did not induce the expression of double-strand break repair
genes. It will be interesting to determine whether ER mutants
lacking phosphorylation sites or transcriptional activation
domains can inhibit the effects of E2 on double-strand break
repair and breast cancer cell survival.
BRCA1 is phosphorylated by ATM kinase, which detects dou-
ble-strand DNA breaks (reviewed in [40]). BRCA1 is phospho-
rylated at carboxyl-terminal serine residues and colocalizes
with histone H2AX and Rad proteins at sites of double-strand
break repair [41,42]. BRCA1-null cells are sensitive to double-
strand breaks and are deficient in repairing this type of DNA
damage [43,44]. BRCA1 represses E2-responsive gene
expression and ER transcriptional activity, which may link the
functions of BRCA1 to specific target tissues [45]. BRCA1
can bind directly to ER independently of E2 through the amino
terminus of the tumor suppressor and the carboxyl domain of
the receptor [46]. Amino-terminal truncations of BRCA1
blocked the ability of the tumor suppressor to inhibit ER activ-
ity in these studies. However, our results with a mutant
BRCA1 protein showed that despite an intact amino terminus,
the truncated tumor suppressor was not able to inhibit E2-
mediated increases in double-strand break repair and cell
survival. These data suggest a role for the BRCA1 carboxyl ter-
minus in mediating the E2-dependent effects. We showed that
this ligand-mediated protection was correlated with the forma-
tion of ER/coactivator complexes with BRCA1. However,
treatment with RA did not recruit BRCA1 to RAR-CBP het-
erodimers, suggesting a receptor-specific effect. Our studies
demonstrated that in the absence of the BRCT carboxyl
domain, the mutant BRCA1 repressed the expression of mul-
tiple double-strand break repair proteins. Future studies will be
important to examine the mechanisms by which these tran-
scriptional complexes regulate DNA repair genes.
Our results show that the expression of a mutant BRCA1 con-
struct inhibited cell cycle progression in human breast cancer
cell lines, which correlated with decreased sensitivity to dou-
ble-strand breaks. A previous study showed that loss of
BRCA1 function in breast cancer resulted in cell cycle arrest
through p53 and p21 [47]. In agreement with our results, sev-
eral carboxyl-terminal truncated BRCA1 proteins conferred
chemoresistance and decreased susceptibility to apoptosis
[48]. However, a small carboxyl-terminal BRCA1 truncation
caused defective transcriptional activation, cell cycle progres-
sion, and increased sensitivity to double-strand breaks in an
ovarian cancer cell line [49]. These studies illustrate cell-spe-
cific differences in BRCA1 function and show that the
Figure 4
BRCA1delC, but not siRNA, inhibits cell cycle progression in human  breast cancer cell lines BRCA1delC, but not siRNA, inhibits cell cycle progression in human 
breast cancer cell lines. (a) Decreased bromodeoxyuridine (BrdU) 
incorporation in T47D and MDA-MB-468 BRCA1delC (del) clones. 
Neomycin-resistant clones were used as controls. Separate cultures 
were transiently transfected with BRCA1 siRNA. Clones were treated 
with etoposide (E) as described in Materials and Methods. These 
experiments were performed three times with similar results. Error bars 
indicate SEM. (b) T47D and MDA-MB-468 BRCA1delC and neomy-
cin-resistant control (neo) clones were treated with etoposide (etopo) 
or vehicle prior to western blotting with the anti-cell-cycle-regulatory 
antibodies indicated at the left. Blots were stripped and incubated with 
anti-β-actin antibody to determine the relative amounts of protein in 
each lane. Representative blots are shown.Breast Cancer Research    Vol 8 No 1    Crowe and Lee 
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Figure 5
E2-dependent effects on DNA damage and cell survival are mediated by the expression of ERα E2-dependent effects on DNA damage and cell survival are mediated by the expression of ERα. (a) ER-negative MDA-MB-468 cells were stably 
transfected with estrogen receptor α (ERα) expression vector (ER) or neomycin resistance plasmid (neo). ER-positive T47D neomycin-resistant con-
trol clones (neo) were used for comparison of ERα expression. Blots were stripped and incubated with anti-β-actin antibody to determine relative 
amounts of protein in each lane. (b) Complex formation of BRCA1 with CBP and ERα in MDA-MB-468 ERα stable clones treated with E2 but not 
with RA. Vehicle-treated cells were used as the negative control. The CBP coactivator protein was immunoprecipitated from treated cultures with 
anti-CBP antibody (IP CBP). Preimmune IgG was used as the negative control for immunoprecipitation. Immunoprecipitates were subjected to west-
ern blotting to detect interaction with ERα, retinoic acid receptor α (RARα), and BRCA1 by using the antibodies indicated at the left. The experi-
ments were performed three times with similar results; representative blots are shown. (c) E2 inhibits DNA damage in MDA-MB-468 clones stably 
expressing ERα. Neomycin-resistant control clones (neo) were used as controls. ER-positive T47D neomycin-resistant control clones (T47D neo) 
were used for comparison. Cultures were treated with E2 or RA alone or in combination (E2/RA) as described in Materials and Methods. Vehicle-
treated clones were used as negative controls (con). Relative DNA damage was quantified with the single-cell gel electrophoresis assay. Error bars 
indicate SEM. (d) Ectopic ER expression in ER-negative MDA-MB-468 cells is sufficient to mediate the effects of E2 on DNA repair activity. Neomy-
cin-resistant control clones (neo) were used as controls. ER-positive T47D neomycin resistant control clones (T47D neo) were used for comparison. 
Cultures were treated with E2 or RA alone or in combination (E2/RA) as described in Materials and Methods. Vehicle-treated clones were used as 
negative controls (con). Relative DNA repair activity was quantified by the plasmid end-joining assay. Error bars indicate SEM. (e) E2 increases cell 
survival in MDA-MB-468 clones stably expressing ERα. Neomycin-resistant control clones (neo) were used as controls. ER-positive T47D neomycin-
resistant control clones (T47D neo) were used for comparison. Cultures were treated with E2 or RA alone or in combination (E2/RA) as described 
in Materials and Methods. Vehicle-treated clones were used as negative controls (con). Apoptotic cells were identified by TdT-mediated dUTP nick 
end labelling assay. Error bars indicate SEM.Available online http://breast-cancer-research.com/content/8/1/R1
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carboxyl-terminal domain needs to be better defined if we are
to understand its effects on these diverse cellular processes.
Our results demonstrated that treatment with E2 resulted in
complex formation between ERα, CBP, and BRCA1 in ER-
positive breast cancer cell lines. ERβ has been shown to
inhibit the proliferation and E2-dependent stimulation of breast
cancer cell lines [50,51]. It will be interesting to determine
whether ERβ differentially affects the response to DNA dam-
age in human breast cancer cells. Treatment with RA recruited
CBP but not BRCA1 to RARα in both ER-positive and ER-
negative cell lines. The carboxyl-terminal domain of CBP has
been shown to interact in vitro and in vivo with BRCA1 [52].
BRCA1 interaction with CBP and p300 was shown to occur
in a phosphorylation-independent manner through the CREB-
binding domain of the coactivators and both the amino and
carboxyl termini of the tumor suppressor [24]. The ability of
BRCA1 to repress ER-responsive gene expression was corre-
lated with its ability to downregulate the expression of p300
but not that of [53]. Increased expression of CBP or p300 res-
cued the inhibition of ER-responsive genes by BRCA1, per-
haps by displacing BRCA1 from the nuclear receptor.
Sequence comparisons between ER and RAR may reveal
important differences between these receptors that function-
ally regulate their interactions with coactivators and BRCA1.
Conclusion
E2 and RA had opposing effects on the survival of ER-positive
breast cancer cell lines MCF7 and T47D after double-strand
DNA break damage. Signaling pathways upstream of ER had
no effect on the survival-promoting effect of E2. The cell sur-
vival effects of E2 and RA on the ER-positive human breast
cancer cell lines were correlated with relative DNA damage
levels in cultures treated with etoposide. The effects of E2 and
RA on DNA damage were correlated with DNA repair activity
in ER-positive human breast cancer cell lines. Treatment with
E2 resulted in the formation of a complex between ERα, CBP,
and BRCA1 in ER-positive breast cancer cell lines. Treatment
with RA recruited CBP but not BRCA1 to RARα in both ER-
positive cell lines and the ER-negative cell lines MDA-MB-231
and MDA-MB-468. Mutant BRCA1 expression reduced the
expression of DNA damage repair proteins and was correlated
with increased etoposide-mediated DNA damage in these
lines but did not block nuclear hormone-dependent effects.
Expression of the BRCA1 mutant resulted in decreased DNA
repair activity in ER-positive and ER-negative breast cancer
clones. Despite decreased DNA repair as the result of mutant
BRCA1 expression, this construct produced increased sur-
vival in breast cancer cells with DNA double-strand breaks.
The truncated BRCA1 failed to form complexes with ERα and
CBP; this was correlated with its ability to exert E2-independ-
ent effects on DNA damage repair. The mutant BRCA1 con-
struct, but not BRCA1 siRNA, inhibited cell cycle progression,
which was correlated with increased resistance to etoposide.
Ectopic ERα expression was sufficient to produce the E2-
mediated effects on relative DNA damage levels, DNA repair,
and survival in etoposide-treated MDA-MB-468 clones.
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